Yes. In the trial that led to UK approval, adults taking the Wegovy pill lost an average of 13.6% of their body weight over 64 weeks, rising to 16.6% among those who stayed on treatment, against roughly 2% on placebo.
But do Wegovy pills work is really two questions. Does the medicine work, and will it work for you. The first has a clear answer. The second depends almost entirely on something most guides mention only in passing.
Do Wegovy pills work? What the trial actually found
The evidence comes from OASIS 4, a 64 week randomised trial of 307 adults with obesity, or overweight with at least one weight-related condition. Adults with type 2 diabetes were excluded. Two thirds took oral semaglutide 25 mg daily, one third took a placebo, and everyone followed a reduced-calorie diet and increased activity.
The headline results:
-
13.6% average weight reduction counting everyone who started, against 2.2% on placebo
-
16.6% among those who adhered to treatment, against 2.7%
-
Around 30% lost a fifth of their body weight or more, against roughly 3% on placebo
-
Improvements were also seen in waist circumference, cholesterol and blood sugar markers
One detail rarely reported is worth noting. Fewer people stopped treatment in the Wegovy group than in the placebo group, 18% against 26%. That is not what you would expect if the side effects were intolerable for most people.
Why you keep seeing two different numbers
If you have searched this before, you will have found 13.6% on one page and 16.6% or 14% on another, with no explanation. Both come from the same trial.
Trials report results using different estimands, which is a technical way of saying “who are we counting”.
The treatment-policy figure counts everyone randomised, including people who stopped early or added other interventions. That is 13.6%, and it is the conservative, realistic number for a general population.
The on-treatment figure counts only those who took the medicine as directed throughout. That is 16.6%, and it tells you what the drug can do when taken properly.
Neither is wrong. The useful move is to know which one you are being shown, because a comparison that uses the flattering figure for one medicine and the conservative one for another is not a comparison at all.
Do Wegovy pills work as well as the shot?
Broadly, yes, at standard doses.
The Wegovy injection at 2.4 mg weekly produced around 15% average reduction in its pivotal trial. The pill at 25 mg daily produced around 14%. Those are separate trials with different designs, so they cannot be compared directly, but the two sit close enough that the choice is usually about routine rather than results.
The distinction that does matter is the higher injection dose. A 7.2 mg weekly injection became available in 2026 and produced larger average reductions than either standard option. There is no equivalent higher-strength pill.
So if you want the largest average figure, that sits with injections. If you want to avoid needles and the numbers at standard dose are close enough for you, the tablet is a genuine alternative rather than a compromise. We cover the full picture in our guide to Wegovy tablets in the UK.
How long do Wegovy pills take to work?
Two timelines run at once, and conflating them is why people think the tablet has failed when it has not.
Appetite changes come first, often within the first week or two. Smaller portions feel like enough, and snacking tends to drop off.
Visible weight change takes longer, because the dose builds slowly. Treatment starts at 1.5 mg and steps up through 4 mg and 9 mg to the 25 mg maintenance dose, with roughly a month at each level. That means you do not reach the full dose until around month four.
The 64 week trial figures were produced over more than a year. Judging the tablet at week six, while still on a starting dose, is judging it before it has been given a chance.
The thing that decides whether it works for you
Here is the part the forum threads miss entirely, and it matters more for the tablet than for any injection.
Semaglutide is a peptide, which the gut breaks down readily. To survive that, the tablet is paired with an absorption enhancer that works in a small area of the stomach, briefly. Even then, only a very small fraction of each dose reaches the bloodstream.
That is why the administration rules are so specific. The tablet must be taken first thing in the morning after fasting, with no more than a sip of plain water, and nothing else by mouth for 30 minutes.
Those are not comfort instructions. Eating, drinking or taking other oral medicines inside that window measurably reduces how much semaglutide you absorb. If someone tells you the pill did not work for them, the first question worth asking is whether they held the window every morning.
Which brings the honest answer into focus. Do Wegovy pills work? Yes, if the routine is workable for you. If your mornings are chaotic, you take levothyroxine, or you work shifts, the tablet may underperform for reasons that have nothing to do with the medicine. In that situation an injection, or Foundayo, which has no fasting requirement, may suit you better.
Who it is licensed for
The MHRA approved the Wegovy pill on 11 June 2026, the first GLP-1 tablet licensed for weight management in the UK. It is licensed for adults with a BMI of 30 or above, or 27 to 30 with at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity.
It is a prescription-only medicine, is not currently funded on the NHS, and is not licensed for type 2 diabetes. Common side effects are gastrointestinal: nausea, diarrhoea, constipation and vomiting, typically most noticeable early and after each dose increase. Our guide to Wegovy safety covers the full profile.
Frequently asked questions
How do Wegovy pills work?
Semaglutide mimics GLP-1, a hormone released by the gut after eating. It acts on appetite centres in the brain, slows stomach emptying and supports blood glucose regulation, so you feel full on less.
Do the Wegovy pills work without diet changes?
They are licensed as an adjunct to a reduced-calorie diet and increased activity. The trial results were produced alongside both.
How long do Wegovy pills take to work on appetite?
Usually within the first week or two, well before the scale reflects it.
What if I miss the morning window?
Absorption is reduced for that dose. Do not take a second tablet. Resume the correct routine the next morning.
Can I switch from the injection to the pill?
Often yes, and your prescriber will advise the starting dose. The fasted routine then applies.
Patients based in Europe are served by Medetone, and those in the United States by Medetone US.
The short version
Do Wegovy pills work? The trial says 13.6% average reduction over 64 weeks counting everyone, 16.6% among those who stayed on treatment, which puts the tablet close to the standard injection dose. Appetite shifts within weeks, the full dose is not reached until around month four, and absorption depends on holding a fasted morning window every single day. The medicine works. Whether it works for you is mostly a question of whether that routine fits your life.
“When someone tells me the tablet is not working, we almost always find the morning window has slipped. Coffee at twenty minutes instead of thirty, or a tablet taken with breakfast. The medicine is not failing. The absorption is.”
Dr Abdullah Alhasan, Medical Director at Rightangled
Semaglutide carries Black Triangle status in the UK, meaning additional MHRA monitoring. Report suspected side effects through the MHRA Yellow Card scheme. Every weight management consultation at Rightangled is reviewed by GPhC-registered independent prescribers as soon as the consultation is submitted.
You can review Wegovy tablets, compare the full range of weight management treatments, or begin a clinical assessment to find out which options you are eligible for.
Verify us before you trust us
References
1. MHRA. First GLP-1 tablet for weight loss approved in the UK. GOV.UK, 11 June 2026. MHRA approval press release
2. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). N Engl J Med, 2025. OASIS 4 trial on PubMed
3. NICE. Semaglutide for managing overweight and obesity, TA875. NICE technology appraisal TA875
4. MHRA. Drug Safety Update, GLP-1 receptor agonists. October 2024. MHRA Drug Safety Update on GLP-1 receptor agonists
This article is for information only and is not a substitute for individual medical advice. Semaglutide is a prescription-only medicine. Suitability, dosing and expected outcomes vary between individuals and must be assessed by a prescriber. Always read the patient information leaflet supplied with your medicine. Last reviewed November 2026.
